Introduction
============

Breast cancer (BC) is the second most frequent cause of cancer-related deaths in women worldwide. It is a heterogeneous disease composed of multiple subtypes with distinct pathological features and clinical implications. Although men are affected, to a lesser degree, the most significant risk factors are gender (women) and older age. Other risk factors include obesity, estrogen exposure, alcohol consumption, and a family history.[@b1-bctt-10-131] Over the past 2 decades, accumulating evidence, both clinical and experimental, has suggested that BCs with different histopathological and biological features exhibit distinct behaviors that lead to different treatment responses and, therefore, should be given different therapeutic strategies.[@b2-bctt-10-131] On this basis, at diagnosis, BC patients are systematically tested for the presence of receptors, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), in order to explore tailored treatment options with molecularly targeted therapies. However, for patients who are triple negative (ER-, PR-, and HER2-), those who have innate or acquired resistance to targeted therapies, and patients whose disease has metastasized, traditional treatment options including surgery, radiotherapy, and chemotherapy are favored.

Anthracycline-based chemotherapy with doxorubicin (DOX) is one of the most efficacious anticancer agents for both early- and late-stage BCs.[@b3-bctt-10-131] DOX's mechanism of action ([Figure 1](#f1-bctt-10-131){ref-type="fig"}) on cancer cells begins with its passive diffusion through the phospholipid bilayer membrane of malignant cells into the cytoplasm, where DOX is converted into a semiquinone and generates reactive oxygen species (ROS), causing free radical formation and oxidative stress. In the cytosol, DOX enters the mitochondria causing DNA damage and energetic stress. As a result, the mitochondria release the cytochrome *C* protein, triggering the caspase cascade leading to cell death. From the cytosol, DOX translocates into the nucleus where it intercalates between double-stranded DNA helices and inhibits the enzymes topoisomerases I and II. The resulting damage to DNA leads to free radical generation, alkylation, and activation of the p53 pathway, hence inhibiting cell proliferation and inducing apoptosis. DOX can also hyperactivate the nuclear enzyme poly ADP ribose polymerase (PARP)-1, hence depleting the cell's energy, thereby resulting in autophagy.[@b4-bctt-10-131]--[@b6-bctt-10-131]

However, the potential therapeutic benefits of DOX are limited by the risk of cardiotoxicity, which has been evidently related to its lifetime cumulative dose.[@b7-bctt-10-131]--[@b9-bctt-10-131] To overcome this hurdle, the liposomal DOX (L-DOX) formulation was developed in order to reduce DOX-associated cardiotoxicity while preserving its antitumor efficacy.[@b10-bctt-10-131] The L-DOX formulation encapsulates DOX within a phospholipid bilayer that is coated with methoxypolyethylene glycol ([Figure 2](#f2-bctt-10-131){ref-type="fig"}). The PEGylation protects the liposomes from recognition by the mononuclear phagocyte system (MPS) and allows a longer circulation time in the bloodstream while reducing the exposure of free DOX circulating in the plasma. Biodistribution studies have shown that L-DOX has the ability to deposit and/or penetrate tumors and release DOX.[@b11-bctt-10-131] Although the mechanism of release of DOX from its liposomes is still unknown, a 10-fold higher exposure of L-DOX than DOX is observed in metastatic BC tissue as compared to healthy breast tissue,[@b12-bctt-10-131] which is explained by the enhanced permeability retention effect.[@b13-bctt-10-131] This indicates that a therapeutic approach with L-DOX is more targeted compared to DOX. A differential pharmacokinetic (PK) characteristic between the two formulations includes a decreased clearance (CL), a smaller volume of distribution, and a longer half-life for L-DOX compared to DOX as a result of the sequestration of liposomes, due to their increased size, in the sinusoidal lumen of the liver, which limits their flow from the fenestrations of the lumen into the hepatocytes as compared to free DOX. This is also believed to contribute to reduced hepatic extraction of L-DOX compared to DOX as a single agent.[@b14-bctt-10-131] The latter being primarily metabolized in the liver to the major cytotoxic metabolites: doxorubicinol and cytotoxic aglycones. The PK properties of L-DOX as compared to DOX are summarized in [Table 1](#t1-bctt-10-131){ref-type="table"}.

The use of DOX as a stand-alone treatment has shown effectiveness in overall survival and response rate and time to disease progression.[@b15-bctt-10-131] Its limitations are seen in its effect on healthy cells and the resulting adverse effects, with the most significant being cardiotoxicity. The comparison of safety profiles between DOX and L-DOX is summarized in [Table 2](#t2-bctt-10-131){ref-type="table"} with the most common side effect for L-DOX being palmar--plantar erythrodysesthesia, a skin toxicity that can be managed with supportive care, unlike cardiotoxicity, which is significantly more prevalent for DOX.[@b16-bctt-10-131] Although the mechanism of DOX-induced cardiotoxicity is not fully understood, its administration is dose limited. It was shown that the risk of DOX-induced cardiotoxicity increases with the increase in its cumulative lifetime dose to becoming irreversible (ie, cardiomyocytes death) when the latter reaches 450--550 mg/m^2^.[@b17-bctt-10-131] The other major cardiotoxic effects of DOX are the occurrence of congestive heart failure (CHF) in \>20% of the treated patients.[@b8-bctt-10-131] Additional but less detrimental adverse reactions include nausea, vomiting, gastrointestinal problems, neurological symptoms, and cutaneous injuries at the site of injection.[@b4-bctt-10-131]

While L-DOX has proven to be advantageous over DOX as a single agent, it is only indicated in the treatment of metastatic BC in combination with docetaxel,[@b18-bctt-10-131] although it is frequently utilized as adjuvant therapy in metastatic BC.[@b19-bctt-10-131] The comparative anticancer efficacies of these two drugs in addition to their use in combination with other anticancer agents in BC continue to be investigated.[@b20-bctt-10-131] [Table 3](#t3-bctt-10-131){ref-type="table"} summarizes the main findings of trials assessing regimens containing L-DOX. These trials evaluated the efficacy of several combinations in varied patient populations including both locally advanced and metastatic BCs as well as the elderly and in patients with previously treated BCs. Overall, L-DOX was effective and well tolerated in the majority of trials, making it a feasible treatment option when combined with other chemotherapeutics. In the present work, we sought to investigate L-DOX's efficacy on BC and its potential associated cardiac toxicity when combined with other chemotherapeutic or targeted therapy, with the goal of showcasing the beneficial effect of L-DOX over DOX on BC therapy and cardiac function.

Methods
=======

A literature search was conducted on PubMed, Google Scholar, and ClinicalTrials.gov using the following main keywords: liposomal DOX, Doxil^®^ and BC, Caelyx^®^ and BC, and Doxil^®^ or Caelyx^®^ and combinations in BC, to obtain relevant publications evaluating the safety and efficacy of L-DOX in the treatment of breast tumors. Additionally, information regarding the PK and safety profiles of L-DOX and conventional DOX was acquired mainly from drug monographs. Publications assessed in this review included Phases II and III clinical trials of patients with BC, ranging from early to metastatic stages. No particular preference was given in regard to BC subtype, and the only criteria that needed to be met for combinations were the use of L-DOX in at least one arm with at least one additional agent.

Results
=======

[Tables 1](#t1-bctt-10-131){ref-type="table"} and [2](#t2-bctt-10-131){ref-type="table"} highlight the disparity in PK parameters and toxicity profiles between L-DOX and DOX. These can be attributed to differences in the formulation of the two agents, with the encapsulation of free DOX into a phospholipid bilayer and exterior PEGylation of the liposomes providing improvements in terms of increasing the drug's half-life (*T*~1/2~), decreasing both the volume of distribution (*V*~d~) and plasma CL, and reducing the severity of toxicity associated with the use of anthracyclines. L-DOX's decreased CL (\~ 0.7 vs 324--809 mL/ min/m^2^ for DOX) and increased *T*~1/2~ (55±4.8 vs 20--48 h for DOX) may be attributed to decreased metabolism by the liver and MPS. L-DOX liposomes are \~80--90 nm in diameter, although some references state that the size of the molecule is ≥100 nm, a characteristic that impedes their passage across hepatic sinusoidal epithelial fenestrations and decreases their metabolism by hepatocytes. In addition, PEGylation of liposomes decreases their opsonization by immunoglobulin/ complement proteins and their uptake by phagocytic cells of the MPS (eg, Kupffer cells and splenic macrophages), thus prolonging the agent's plasma circulation time.

Another advantage of L-DOX is its extremely small volume of distribution in comparison to that of DOX (2.72±0.12 vs 809--1,214 L/m^2^). While DOX's large *V*~d~ indicates that it can effectively distribute into all compartments of the body, its lack of selectivity for tumors means that it can cause a wide range of toxicities. In contrast, the small volume of distribution of L-DOX indicates that the drug is mostly confined into the vascular space, with little free DOX available, as the drug is contained within the liposomes and does not distribute freely to healthy tissues. The small size of L-DOX allows it to extravasate more selectively across fenestrations in the epithelium of blood vessels supplying tumors, where it releases DOX, meaning that generally the use of L-DOX is associated with milder side effects.[@b5-bctt-10-131],[@b14-bctt-10-131] The classic adverse effect associated with DOX use is cardiotoxicity that can range in severity from an acute form that develops shortly after exposure to DOX to a more severe late form where patients may experience decreases in left ventricular ejection fraction (LVEF) and a subsequent diagnosis of DOX induced CHF. Furthermore, the use of DOX is limited by a cumulative lifetime dose limit of up to 550 or 450 mg/m^2^ if a patient received previous mediastinal radiation. In contrast, the more common toxicities from L-DOX use include palmar--plantar erythrodysesthesia, nausea, and alopecia.[@b16-bctt-10-131],[@b21-bctt-10-131]--[@b25-bctt-10-131]

Since DOX is considered one of the most effective chemotherapy drugs available, it is often added to regimens for localized or metastatic BC as first- or second-line therapy, as a part of a neoadjuvant therapy prior to surgery or as a salvage therapy. Although it is an effective agent, the risks of cardiotoxicity, particularly when combined with other medications associated with the development of CHF, such as trastuzumab and cyclophosphamide, can limit its use.[@b26-bctt-10-131] In the case of L-DOX, the decreased rates of cardiotoxicity due to the formulation/PK differences described in the preceding paragraph allows its inclusion in regimens where free DOX would have a high risk of cardiotoxicity. [Table 3](#t3-bctt-10-131){ref-type="table"} summarizes several trials where L-DOX has been combined with other chemotherapeutics or targeted therapies. Of note, a study combining L-DOX, trastuzumab, and cyclophosphamide was one of the most effective, with an overall survival of 34.2 months and the progression-free survival (PFS) of 12 months.[@b27-bctt-10-131] In terms of toxicity, eight of the 48 included patients experienced asymptomatic decreases in LVEF and all but one recovered; of the affected patients, six patients had prior exposure to anthracyclines. As for the other trials included in [Table 3](#t3-bctt-10-131){ref-type="table"}, a majority did not find any significant changes to LVEF or high incidences of clinically relevant cardiotoxicity; however, in several instances where mild-to-moderate cardiotoxicity was reported, it was often in patients who either had prior anthracycline exposure or were concurrently being treated with trastuzumab.[@b27-bctt-10-131]--[@b31-bctt-10-131]

Discussion
==========

The decreased risk for the cardiotoxicity of L-DOX combined with its comparable efficacy to DOX in the treatment of BC has made it a suitable alternative therapy in treatment regimens that traditionally utilized conventional DOX.[@b16-bctt-10-131] In the in vivo setting, the prolonged systemic circulation of L-DOX due to its relatively long half-life,[@b32-bctt-10-131] along with its selective delivery to the tumor site due to its extravasation through leaky tumor vasculature,[@b33-bctt-10-131] results in a higher tumor accumulation as compared to normal tissues. In addition, circulating free-drug concentrations in plasma are reduced due to the highly stable L-DOX formulation, leading to lower cardiac tissue exposure of free-DOX, as compared to tumor tissue. Thus, the use of L-DOX would not only be able to alleviate cardiotoxicity but also to retain significant cytotoxic activity against target tumor cells, due to differences in exposure as well as relative potency of DOX in both tissue types. This is in agreement with results from a Phase III study,[@b16-bctt-10-131] where L-DOX was shown to be as efficacious as DOX, with significantly reduced cardiotoxicity and other adverse events, in patients with metastatic BC.

[Table 3](#t3-bctt-10-131){ref-type="table"} summarizes all clinical trials for combinatorial effects of L-DOX with other chemotherapeutics and targeted agents. It is noted that practically all trials are Phase II, and the cardiotoxic events observed were either very low or not existent. In most cases where patients experienced mild-to-moderate cardiotoxicity, they were reported to have received prior anthracycline therapy or were on regimens that included trastuzumab, which is known to augment cardiotoxicity caused due to DOX.[@b34-bctt-10-131] Nevertheless, the cardiotoxicity observed in the case of L-DOX was significantly lower than that observed with DOX, thus establishing the cardiac safety of this formulation and supporting its clinical use.

In this work, we sought to discuss the therapeutic use of L-DOX in BC. A review of available Phase II and III trials in BC patients has demonstrated that the use of L-DOX generally causes very little cardiotoxicity, while retaining efficacy when used in combination with other chemotherapeutics. Together, this information suggests that L-DOX should continue to be evaluated in further Phase II and III trials in BC, as it remains an effective agent when combined with other chemotherapeutics and is a reasonable agent to substitute in the place of conventional DOX, particularly in patients who are at higher risk for cardiotoxicity.
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![Mechanism of action of DOX and L-DOX.\
**Notes:** Once L-DOX diffuses across the phospholipid bilayer of malignant cells, free DOX is released and it can be converted into a semiquinone or translocate into the nucleus or mitochondria. Conversion of DOX to a semiquinone causes the formation of ROS. DOX can also translocate to the nucleus where it intercalates between strands of DNA, inhibits topoisomerases I and II and activates PARP-1. In the mitochondria, DOX intercalates between strands of mitochondrial DNA and leads to the release of cytochrome *C* and the activation of caspases. Ultimately, damage to nuclear and mitochondrial DNA as well as that caused by ROS leads to apoptosis.\
**Abbreviations:** DOX, doxorubicin; L-DOX, liposomal DOX; PARP, poly ADP ribose polymerase; ROS, reactive oxygen species.](bctt-10-131Fig1){#f1-bctt-10-131}

![PEGylated liposomal DOX (Doxil^®^).\
**Notes:** DOX is surrounded by a phospholipid bilayer (liposome) that is coated with methoxypolyethylene glycol. Enclosing DOX in a liposome helps decrease systemic side effects while PEGylation protects the liposomes from recognition by the mononuclear phagocyte system and increases its circulation time.\
**Abbreviation:** DOX, doxorubicin.](bctt-10-131Fig2){#f2-bctt-10-131}

###### 

Pharmacokinetic properties of DOX and L-DOX

  Parameter (unit)   Definition                          DOX, min--max[@b35-bctt-10-131]                 L-DOX, average ± SD[@b36-bctt-10-131]
  ------------------ ----------------------------------- ----------------------------------------------- ---------------------------------------
  CL (mL/min/m^2^)   Plasma clearance                    324--809                                        0.683±0.066
  *T*~1/2~ (h)       Half-life                           20--48                                          55±4.8
  *V*~d~ (L/m^2^)    Volume of distribution              809--1,214                                      2.72±0.12
  *F*~b~ (%)         Fraction bound to plasma proteins   75[a](#tfn1-bctt-10-131){ref-type="table-fn"}   Not determined

**Note:**

Data shown as average.

**Abbreviations:** CL, clearance; DOX, doxorubicin; L-DOX, liposomal DOX; SD, standard deviation.

###### 

Comparison of use, efficacy, and safety profiles of DOX and L-DOX

  Criteria                                               DOX[@b16-bctt-10-131],[@b21-bctt-10-131],[@b23-bctt-10-131]                                                     L-DOX[@b16-bctt-10-131],[@b22-bctt-10-131],[@b24-bctt-10-131]
  ------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  Indications                                            Label: leukemia, bladder cancer, breast cancer, gastric cancer, sarcomas, small cell lung cancer among others   Label: Kaposi's sarcoma, multiple myeloma, and ovarian cancer
  Off label: biliary tract cancer, endometrial cancer,   Off label: use for breast cancer, cutaneous                                                                     
  Kaposi's sarcoma, malignant melanoma                   T-cell lymphoma                                                                                                 
  Maximum dose limits                                    Lifetime: up to 550 mg/m^2^ IV                                                                                  50 mg IV weekly
  Up to 450 mg IV if previous mediastinal radiation      Safety and efficacy have not been established in children and adolescents                                       
  Black box warnings                                     Bone marrow suppression, cardiotoxicity, extravasation                                                          Cardiotoxicity and infusion-related reactions
  Adverse effects                                        Cardiotoxicity                                                                                                  Palmar--plantar erythrodysesthesia
  Nausea/vomiting                                        Nausea/vomiting                                                                                                 
  Alopecia                                               Alopecia                                                                                                        
  Leukopenia/neutropenia                                 Cardiotoxicity                                                                                                  
  Palmar--plantar erythrodysesthesia                     Leukopenia/neutropenia                                                                                          

**Abbreviations:** DOX, doxorubicin; L-DOX, liposomal DOX; IV, intravenous.

###### 

Clinical trials with L-DOX in combination with other chemotherapeutics in breast cancer

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drugs                                                                                                                                                                                 Clinical trial                                                                                                                                                      Main findings                                References
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------
  PLD and bevacizumab                                                                                                                                                                   Phase II                                                                                                                                                            46% of patients had grade three toxicities   [@b37-bctt-10-131]

  \- 20 mg/m^2^ PLD and 10 mg/kg bevacizumab given days 1 and 15 of 4-week cycle                                                                                                        ORR: 21%                                                                                                                                                                                                         

  Median PFS: 5.7 months                                                                                                                                                                                                                                                                                                                                                                                 

  Median OS: 15.9 months                                                                                                                                                                                                                                                                                                                                                                                 

  Severe cardiotoxicity in one patient 4.7 months after treatment                                                                                                                                                                                                                                                                                                                                        

  PLD and bortezomib                                                                                                                                                                    Phase II                                                                                                                                                            ORR: 8%                                      [@b38-bctt-10-131]

  \- 1.3 mg/m^2^ bortezomib days 1, 4, 8, and 11 and 30 mg/m^2^ PLD day 4 of 21-day cycle                                                                                               Median OS: 4.3 months                                                                                                                                                                                            

  Median TTP: 1.3 months                                                                                                                                                                                                                                                                                                                                                                                 

  No cardiotoxicity reported despite prior anthracycline use in 77% of patients                                                                                                                                                                                                                                                                                                                          

  PLD and carboplatin (+ trastuzumab if HER2+)                                                                                                                                          Phase II                                                                                                                                                            PLD/carboplatin                              [@b39-bctt-10-131]

  1A: taxane naive                                                                                                                                                                                                                                                                                                                                                                                       

  30 mg/m^2^ PLD and carboplatin AUC = 5 mg^\*^min/mL day 1 of 21-day cycle                                                                                                             ORR: 31%                                                                                                                                                                                                         

  Median PFS: 8 months                                                                                                                                                                                                                                                                                                                                                                                   

  If HER2+ also got 8 mg/kg loading dose of trastuzumab and then 4 mg/kg days 1 and 15 of 28-day cycle                                                                                  1B: taxane pretreated                                                                                                                                                                                            

  ORR: 31%                                                                                                                                                                                                                                                                                                                                                                                               

  Median OS: 13 months                                                                                                                                                                                                                                                                                                                                                                                   

  Median PFS: 5 months                                                                                                                                                                                                                                                                                                                                                                                   

  PLD/carboplatin/trastuzumab                                                                                                                                                                                                                                                                                                                                                                            

  ORR: 56%                                                                                                                                                                                                                                                                                                                                                                                               

  Median OS: 33 months                                                                                                                                                                                                                                                                                                                                                                                   

  Median PFS: 10 months                                                                                                                                                                                                                                                                                                                                                                                  

  No clinically significant cardiotoxicity. Declines in LVEF of at least                                                                                                                                                                                                                                                                                                                                 

  15% in two patients in arm 1A and one patient in trastuzumab arm                                                                                                                                                                                                                                                                                                                                       

  PLD, cisplatin, infusional 5-FU, and trastuzumab                                                                                                                                      Phase II                                                                                                                                                            Clinical response rate: 94%                  [@b31-bctt-10-131]

  2-year DFS: 94%                                                                                                                                                                                                                                                                                                                                                                                        

  25 mg/m^2^ PLD, 60 mg/m^2^ cisplatin day 1 and 200 mg/m^2^ 5-FU as a continuous infusion days 1--21 of 21-day cycle\                                                                  No relevant cardiotoxicity -- two patients had asymptomatic, transient declines in LVEF of at least 20%, but absolute LVEF was maintained above 50% in both cases                                                
  8 mg/kg trastuzumab loading dose then 6 mg/kg on day 2 of cycle                                                                                                                                                                                                                                                                                                                                        

  PLD and cyclophosphamide                                                                                                                                                              Phase II                                                                                                                                                            Objective response: 51%                      [@b40-bctt-10-131]

  Cohort I: 50 mg/m^2^ PLD day 1 and 100 mg/m^2^ cyclophosphamide orally days 1--14 (28-day cycle)                                                                                      Clinical benefit rate (complete response + partial response + stable disease): 86%                                                                                                                               

  Median DOR: 35.1 weeks                                                                                                                                                                                                                                                                                                                                                                                 

  Cohort II: 30 mg/m^2^ PLD and 600 mg/m^2^ cyclophosphamide day 1 of 21-day cycle                                                                                                      Median time-to-tumor progression: 34.4 weeks                                                                                                                                                                     

  No clinical cardiotoxicity or significant declines in median LVEF following treatment                                                                                                                                                                                                                                                                                                                  

  Cohort III: 35 mg/m^2^ and 600 mg cyclophosphamide day 1 of 21-day cycle                                                                                                                                                                                                                                                                                                                               

  PLD and cyclophosphamide (in elderly patients between 65*--*75 years old)                                                                                                             Phase II                                                                                                                                                            Objective response rate: 28.6%               [@b41-bctt-10-131]

  Median PFS: 8.8 months                                                                                                                                                                                                                                                                                                                                                                                 

  \- 40 mg/m^2^ PLD and 500 mg/m^2^ cyclophosphamide day 1 of 4-week cycle                                                                                                              Median OS: 20.3 months                                                                                                                                                                                           

  Mucositis, myelosuppression in the elderly                                                                                                                                                                                                                                                                                                                                                             

  No reported cardiac toxicity or significant changes in LVEF                                                                                                                                                                                                                                                                                                                                            

  PLD, cyclophosphamide, and 5-FU                                                                                                                                                       Phase II                                                                                                                                                            ORR: 41.9%                                   [@b42-bctt-10-131]

  \- 40 mg/m^2^ PLD, 500 mg/m^2^ cyclophosphamide, and 500 mg/m^2^ 5-FU on day 1 of 21-day cycle                                                                                        Median PFS: 8.2 months                                                                                                                                                                                           

  Median OS: 36.6 months                                                                                                                                                                                                                                                                                                                                                                                 

  No significant changes in LVEF, even after prior anthracycline exposure                                                                                                                                                                                                                                                                                                                                

  PLD, cyclophosphamide, and paclitaxel                                                                                                                                                 Phase II                                                                                                                                                            Overall pCR: 32%                             [@b43-bctt-10-131]

  \- 35 mg/m^2^ PLD, 600 mg/m^2^ cyclophosphamide every 4 weeks, and 80 mg/m^2^ paclitaxel weekly                                                                                       Radiological ORR: 26%                                                                                                                                                                                            

  5-year PFS: 58%                                                                                                                                                                                                                                                                                                                                                                                        

  5-year OS: 62%                                                                                                                                                                                                                                                                                                                                                                                         

  No significant declines in LVEF or ECG changes; five cardiac events reported                                                                                                                                                                                                                                                                                                                           

  PLD, cyclophosphamide, and trastuzumab                                                                                                                                                Phase II                                                                                                                                                            Objective response rate: 68.8%               [@b27-bctt-10-131]

  Median OS: 34.2 months                                                                                                                                                                                                                                                                                                                                                                                 

  50 mg/m^2^ PLD and 600 mg cyclophosphamide every 4 weeks                                                                                                                              Median TTP: 12 months                                                                                                                                                                                            

  No symptomatic CHF; declines in LVEF observed in eight of the                                                                                                                                                                                                                                                                                                                                          

  4 mg/kg trastuzumab loading dose then 2 mg/kg weekly                                                                                                                                  48 patients and reversed in seven patients (six of them had prior anthracycline exposure)                                                                                                                        

  PLD, cyclophosphamide, docetaxel, and trastuzumab (if HER2+)                                                                                                                          Phase II                                                                                                                                                            Objective response rate: 83%                 [@b44-bctt-10-131]

  pCRT: 13%                                                                                                                                                                                                                                                                                                                                                                                              

  35 mg/m^2^ PLD and 600 mg cyclophosphamide on day 1 of 21-day cycle                                                                                                                   Normal LVEF maintained during the study                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                         

  100 mg/m^2^ docetaxel day 1 of 21-day cycle                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                         

  If HER2+ got 8 mg/kg loading dose of trastuzumab then 6 mg/kg day 1 of 21-day cycles                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                         

  PLD and docetaxel                                                                                                                                                                     Phase II                                                                                                                                                            Overall clinical benefit: 47%                [@b45-bctt-10-131]

  Group A: 35 mg/m^2^ PLD on day 1 and 40 mg/m^2^ docetaxel days 1 and 15 of 28-day cycle                                                                                               ORR: 49%                                                                                                                                                                                                         

  High rates of toxicity in both groups                                                                                                                                                                                                                                                                                                                                                                  

  No significant cardiotoxicity                                                                                                                                                                                                                                                                                                                                                                          

  Group B: 30 mg/m^2^ PLD day 1 and 75 mg/m^2^ docetaxel day 2 (3-week cycle)                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                         

  PLD and docetaxel (trastuzumab if HER2+)                                                                                                                                              Phase II                                                                                                                                                            PLD/docetaxel                                [@b46-bctt-10-131]

  ORR: 47.4%                                                                                                                                                                                                                                                                                                                                                                                             

  Group A: 30 mg/m^2^ PLD and 60 mg/m^2^ docetaxel every 3 weeks                                                                                                                        Median PFS: 11 months                                                                                                                                                                                            

  Median OS: 24.6 months                                                                                                                                                                                                                                                                                                                                                                                 

  Group B: 30 mg/m^2^ PLD, 60 mg/m^2^ docetaxel every 3 weeks, and 4 mg/kg trastuzumab loading dose then 2 mg/ kg weekly                                                                PLD/docetaxel/trastuzumab                                                                                                                                                                                        

  ORR: 45.7%                                                                                                                                                                                                                                                                                                                                                                                             

  Median PFS: 10.6 months                                                                                                                                                                                                                                                                                                                                                                                

  Median OS: 31.8 months                                                                                                                                                                                                                                                                                                                                                                                 

  Higher rates of hand foot syndrome                                                                                                                                                                                                                                                                                                                                                                     

  Incidence of CHF \<3% and the addition of trastuzumab did not increase CHF risk                                                                                                                                                                                                                                                                                                                        

  PLD and docetaxel vs docetaxel (in patients who experienced a relapse following adjuvant anthracycline use)                                                                           Phase III                                                                                                                                                           PLD/docetaxel                                [@b47-bctt-10-131]

  Objective response rate: 35%                                                                                                                                                                                                                                                                                                                                                                           

  Median TTP: 9.8 months                                                                                                                                                                                                                                                                                                                                                                                 

  \- 30 mg/m^2^ PLD and 60 mg/m^2^ docetaxel (21-day cycle) vs 75 mg/m^2^ docetaxel (21-day cycle)                                                                                      Median OS: 20.5 months                                                                                                                                                                                           

  Docetaxel                                                                                                                                                                                                                                                                                                                                                                                              

  Objective response rate: 26%                                                                                                                                                                                                                                                                                                                                                                           

  Median TTP: 7 months                                                                                                                                                                                                                                                                                                                                                                                   

  Median OS: 20.6 months                                                                                                                                                                                                                                                                                                                                                                                 

  No significant increase in CHF incidence or LVEF decline with the addition of PLD                                                                                                                                                                                                                                                                                                                      

  PLD and GEM                                                                                                                                                                           Phase II                                                                                                                                                            ORR: 47.8%                                   [@b48-bctt-10-131]

  \- 25 mg/m^2^ PLD day 1 and 800 mg/m^2^                                                                                                                                               Median TTP: 7 months                                                                                                                                                                                             

  GEM on days 1 and 8 of 21-day cycle                                                                                                                                                   Median duration of clinical benefit: 8 months                                                                                                                                                                    

  Mild cardiac toxicity in 4% patients; it was recovered after the end of the study                                                                                                                                                                                                                                                                                                                      

  PLD and GEM                                                                                                                                                                           Phase II                                                                                                                                                            ORR: 52%                                     [@b49-bctt-10-131]

  \- 24 mg/m^2^ PLD day 1 and 800 mg/m^2^ GEM days 1 and 8 (21-day cycle)                                                                                                               Median OS: 16.1 months                                                                                                                                                                                           

  Median TTP: 4.5 months                                                                                                                                                                                                                                                                                                                                                                                 

  Clinical benefit: 78%                                                                                                                                                                                                                                                                                                                                                                                  

  Minimal cardiotoxicity, with a transient decline in LVEF in one patient, who recovered after the end of the study                                                                                                                                                                                                                                                                                      

  PLD and GEM                                                                                                                                                                           Phase II                                                                                                                                                            ORR: 39.1%                                   [@b50-bctt-10-131]

  \- 25 mg/m^2^ PLD and 800 mg/m^2^ GEM days 1 and 8 of 21-day cycle                                                                                                                    Median TTP: 11 months                                                                                                                                                                                            

  Overall clinical benefit: 85.9%                                                                                                                                                                                                                                                                                                                                                                        

  Only one case of cardiac toxicity was observed, despite 41% of patients having undergone prior anthracycline therapy                                                                                                                                                                                                                                                                                   

  PLD, GEM and docetaxel                                                                                                                                                                Phase II                                                                                                                                                            ORR: 74%                                     [@b51-bctt-10-131]

  \- 1,000 mg/m^2^ GEM on day 1 followed by 800 mg/m^2^ GEM, 75 mg/m^2^ docetaxel, and 30 mg/m^2^ PLD on day 8 (3-week cycles)                                                          No cardiotoxicity was observed as per protocol-defined criteria and all patients maintained LVEF \>50%                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                         

  PLD and lapatinib                                                                                                                                                                     Phase II                                                                                                                                                            ORR: 54%                                     [@b52-bctt-10-131]

  \- 1,250 mg lapatinib daily and 40 mg/m^2^                                                                                                                                            Median PFS: 5.8 months                                                                                                                                                                                           

  PLD every 4 weeks                                                                                                                                                                     Median OS: 23.3 months                                                                                                                                                                                           

                                                                                                                                                                                        No cardiac events were observed                                                                                                                                                                                  

  PLD (low dose) and paclitaxel                                                                                                                                                         Phase II                                                                                                                                                            Objective response rate: 74%                 [@b53-bctt-10-131]

  \- 15 mg/m^2^ PLD every other week and 80 mg/m^2^ paclitaxel weekly                                                                                                                   9% pathological complete response on breast and axilla                                                                                                                                                           

  55% had breast conserving surgery                                                                                                                                                                                                                                                                                                                                                                      

  No impairment of cardiac function was observed                                                                                                                                                                                                                                                                                                                                                         

  PLD and paclitaxel                                                                                                                                                                    Phase II                                                                                                                                                            Objective response rate: 80%                 [@b54-bctt-10-131]

  \- 30 mg/m^2^ PLD and 175 mg/m^2^ paclitaxel (3-week cycles)                                                                                                                          Median duration of objective response: 31 weeks                                                                                                                                                                  

  Median time to treatment failure: 45 weeks                                                                                                                                                                                                                                                                                                                                                             

  Decline in LVEF was observed in eight of the 26 patients; however, no clinical signs or symptoms of cardiac toxicity/failure were observed                                                                                                                                                                                                                                                             

  PLD and trastuzumab                                                                                                                                                                   Phase II                                                                                                                                                            Clinical benefit: 50%                        [@b30-bctt-10-131]

  \- 40 mg/m^2^ PLD every 4 weeks and 4 mg/kg trastuzumab loading dose then 2 mg/kg weekly                                                                                              Median PFS: 9.67 months                                                                                                                                                                                          

  Median OS: 16.23 months                                                                                                                                                                                                                                                                                                                                                                                

  Three of the 16 patients developed decline in LVEF; a clinically relevant and symptomatic decrease occurred in only one patient                                                                                                                                                                                                                                                                        

  PLD and trastuzumab                                                                                                                                                                   Phase II                                                                                                                                                            ORR: 52%                                     [@b28-bctt-10-131]

  \- 50 mg/m^2^ PLD every 4 weeks and 4 mg/kg trastuzumab loading dose then 2 mg/kg weekly                                                                                              Median DOR: 11.1 months                                                                                                                                                                                          

  Median PFS: 12 months                                                                                                                                                                                                                                                                                                                                                                                  

  10% of the patients developed protocol-defined cardiotoxicity, albeit without any symptoms of CHF                                                                                                                                                                                                                                                                                                      

  PLD and trastuzumab                                                                                                                                                                   Phase II                                                                                                                                                            ORR: 22%                                     [@b55-bctt-10-131]

  \- 30 mg/m^2^ PLD and 8 mg/kg trastuzumab loading dose then 6 mg/kg (3-week cycles)                                                                                                   Median PFS: 6.5 months                                                                                                                                                                                           

  Median OS: 18.7 months                                                                                                                                                                                                                                                                                                                                                                                 

  Severe cardiotoxicity as per protocol-defined criteria was not recorded. Median LVEF was maintained at 62% throughout the study                                                                                                                                                                                                                                                                        

  PLD and VNB                                                                                                                                                                           Phase II                                                                                                                                                            Objective response rate: 36%                 [@b56-bctt-10-131]

  \- 30 mg/m^2^ PLD day 1 and 20 mg/m^2^                                                                                                                                                Median PFS: 6.7 months                                                                                                                                                                                           

  VNB on days 1 and 8 (3-week cycles)                                                                                                                                                   Median OS: 13.2 months                                                                                                                                                                                           

  No cardiotoxicity was observed                                                                                                                                                                                                                                                                                                                                                                         

  PLD and VNB                                                                                                                                                                           Phase II                                                                                                                                                            ORR: 39%                                     [@b29-bctt-10-131]

  \- 40 mg/m^2^ PLD day 2 and 25 mg/m^2^                                                                                                                                                Median TTP: 6.5 months                                                                                                                                                                                           

  VNB on days 1 and 15 (4-week cycles)                                                                                                                                                  Median OS: 14.5 months                                                                                                                                                                                           

  Four of the 36 patients developed a decline in LVEF (\>15%); all four had received prior anthracycline treatment. There were no clinical symptoms of cardiac failure                                                                                                                                                                                                                                   

  PLD and VNB                                                                                                                                                                           Phase II                                                                                                                                                            ORR: 35%                                     [@b57-bctt-10-131]

  \- 35 mg/m^2^ PLD day 1 and 30 mg/m^2^                                                                                                                                                Median TTP: 7 months                                                                                                                                                                                             

  VNB day 1 (4-week cycles)                                                                                                                                                             Median OS: 13 months                                                                                                                                                                                             

  Three of the 33 patients had a significant decline in LVEF (\<50%); none had clinical cardiac symptoms and cardiac function recovered for two patients after cessation of treatment                                                                                                                                                                                                                    

  EPI/VNB vs PLD/VNB                                                                                                                                                                    Phase II                                                                                                                                                            EPI/VNB:                                     [@b58-bctt-10-131]

  \- 90 mg/m^2^ EPI day 1 and 25 mg/m^2^                                                                                                                                                ORR: 42.6%                                                                                                                                                                                                       

  VNB days 1 and 5 (21-day cycle)                                                                                                                                                       Median PFS: 10.7 months                                                                                                                                                                                          

  40 mg/m^2^ PLD day 1 and 30 mg/m^2^                                                                                                                                                   Median OS: 34.6 months                                                                                                                                                                                           

  VNB days 1 and 15 (4-week cycles)                                                                                                                                                     PLD/VNB:                                                                                                                                                                                                         

  ORR: 52%                                                                                                                                                                                                                                                                                                                                                                                               

  Median PFS: 8.8 months                                                                                                                                                                                                                                                                                                                                                                                 

  Median OS: 24.8 months                                                                                                                                                                                                                                                                                                                                                                                 

  No cases of CHF, two transient LVEF decreases in arm EPI/VNB that resolved in 2 months                                                                                                                                                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** 5-FU, 5-fluorouracil; AUC, area under the concentration curve; CHF, congestive heart failure; DFS, disease-free survival; DOR, duration of response; ECG, electrocardiogram; EPI, epirubicin; GEM, gemcitabine; HER2, human epidermal growth factor receptor 2; L-DOX, liposomal doxorubicin; LVEF, left ventricular ejection fraction; ORR, overall response rate; OS, overall survival; pCR, pathological complete response; pCRT, total pathological complete response; PFS, progression-free survival; PLD, PEGylated L-DOX; TTP, time to progression; VNB, vinorelbine.
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